In re: , Shelnėss

Serial No.: 09/885,894 Filed: June 20, 2001

Page 2 of 7

4

47. (New) The particle of claim 44, wherein said particle forms an amphipathic compound.

- 48. (New) The particle of claim 45, wherein said polar lipid comprises from 0 to 50 percent by weight of said particle.
- 49. (New) The particle of claim 45, wherein said polar lipid comprises from 10 to 50 percent by weight of said particle.
- 50. (New) The particle of claim 45, wherein said polar lipid comprises from 15 to 55 percent by weight of said particle.
- 51. (New) The particle of claim 45, wherein said polar lipid comprises from 1 to 30 percent by weight of said particle.
- 52. (New) The particle of claim 45, wherein said neutral lipid comprises from 0 to 90 percent by weight of said particle.
- 53. (New) The particle of claim 45, wherein said neutral lipid comprises from 0 to 10 percent by weight of said particle.
- 54. (New) The particle of claim 45, wherein said neutral lipid comprises from 30 to 90 percent by weight of said particle.
- 55. (New) The particle of claim 45, wherein said neutral lipid comprises from 2 to 30 percent by weight of said particle.
- 56. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 0.5 to 90 percent by weight of said particle.
- 57. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 50 to 90 percent by weight of said particle.
- 58. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 30 to 80 percent by weight of said particle.

Serial No.: 09/885,894 Filed: June 20, 2001

Page 3 of 7

59. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 0.5 to 10 percent by weight of said particle.

- 60. (New) The particle of claim 46, wherein said formed lipophilic compound is from 0.1 to 90 percent by weight of the particle.
- 61. (New) The particle of claim 47, wherein said formed amphipathic compound is from 0.1 to 90 percent by weight of the particle.
- 62. (New) The particle according to claim 44, wherein said apolipoprotein B further comprises a fused heterologous moiety, where said heterologous moiety is a member of a specific binding pair.
- 63. (New) The particle according to claim 53, wherein said heterologous moiety is a peptide.
- 64. (New) The particle according to claim 53, wherein said heterologous moiety is an antibody.
- 65. (New) The particle according to claim 53, wherein said heterologous moiety is a single chain antibody.
- 66. (New) The particle according to claim 53, wherein said heterologous moiety is a single chain anti HER2 antibody.
- 67. (New) The particle according to claim 44, wherein said particle has a diameter of less than 18 nanometers.
- 68. (New) The particle according to claim 44, wherein said particle has a diameter of from 5 to 5,000 nanometers.
- 69. (New) The particle according to claim 44, wherein said apolipoprotein B protein is selected from the group consisting of apoB6 through apoB74.

Serial No.: 09/885,894 Filed: June 20, 2001

Page 4 of 7

70. (New) The particle according to claim 44, wherein said particle has a neutral core, and wherein said apolipoprotein B protein comprises at least ApoB 19.5.

- 71. (New) The particle according to claim 44, wherein said apolipoprotein B protein is mature Apo B.
- 72. (New) The particle according to claim 44, wherein said apolipoprotein B protein is mammalian Apo B.
- 73. (New) The particle according to claim 44, wherein said apolipoprotein B protein is human Apo B.
- 74. (New) The particle according to claim 45, wherein said at least one polar lipid is a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, glycosphingolipid, lysolipid thereof, or combinations thereof.
- 75. (New) The particle according to claim 45, wherein said at least one neutral lipid comprises a triglyceride, cholesterol, derivative thereof, or combinations thereof.
- 76. (New) The particle according to claim 44, wherein said compound delivery particle is paclitaxel.
- 77. (New) The particle according to claim 44, wherein said particle is a small emulsion particle.
- 78. (New) The particle according to claim 44, wherein said particle is a large emulsion particle.
- 79. (New) The particle according to claim 44, wherein said compound to be delivered is an amphipathic compound, and wherein said amphipathic compound comprises a synthetic lipid.

Serial No.: 09/885,894 Filed: June 20, 2001

Page 5 of 7

80. (New) A pharmaceutical formulation comprising a plurality of lipoprotein compound delivery particles of claim 44.

- 81. (New) The pharmaceutical formulation of claim 80, consisting essentially of said particles in a size of 2 to 20 nanometers in diameter.
- 82. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 5 to 40 nanometers in diameter.
- 83. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 10 to 60 nanometers in diameter.
- 84. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 15 to 100 nanometers in diameter.
- 85. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 25 to 200 nanometers in diameter.
- 86. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 50 to 1,000 nanometers in diameter.
- 87. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 250 to 5,000 nanometers in diameter.
- 88. (New) The pharmaceutical formulation of claim 80, in a pharmaceutically acceptable carrier.
- 89. (New) The pharmaceutical formulation of claim 88, wherein said carrier is an aqueous carrier.
- 90. (New) The pharmaceutical formulation of claim 80, in a sterile lyophilized form.
- 91. (New) A method of delivering a compound to a subject in need thereof, comprising administering a lipoprotein compound delivery particle of claim 44 to said subject in an amount effective to deliver said compound to said subject.

Serial No.: 09/885,894 Filed: June 20, 2001

Page 6 of 7

92. (New) The method according to claim 91, wherein said administering step is selected from the group consisting of parenteral injection, intraveneous injection, and topical administration.